NeurologyLive®

🧬 Two phase 3 trials are underway to evaluate salanersen in presymptomatic newborns with spinal muscular atrophy.

The STELLAR-1 and STELLAR-2 studies will assess outcomes with salanersen alone or following gene therapy.

Presented at the 2026 #MDAconference
#SMA #Neurology #GeneTherapy #RareDisease

🧬 Real-world data suggest motor improvements in children with #SMA after switching to #genetherapy.

A Polish study found patients transitioning from nusinersen or risdiplam to onasemnogene abeparvovec showed gains on motor scales within 6 months. Read more on NeurologyLive!

#Neurology #RareDisease

🥗 Can diet influence cognitive health?

A study of 159,000+ adults found that adherence to healthy dietary patterns was linked to a significantly lower risk of subjective cognitive decline. Read the full article on NeurologyLive!

#Neurology #Alzheimer #BrainHealth #Nutrition

🧠 What’s the largest occupation in the US?

Home health & personal #careaides (nearly 4 million workers) quietly determine whether patients with PD, MS, or stroke stay home or land in the ED.

🆕 commentary explores the workforce crisis behind neurologic care. Read more on NeuroLive!
#Neurology

INSIGHT Launches International Effort to Advance Women’s Neurology Education | NeurologyLive - Clinical Neurology News and Neurology Expert Insights NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

New on NeurologyLive: INSIGHT launches an international initiative to advance education in women’s neurology, addressing sex- and gender-specific differences in neurologic care. 🌍🧠

👉 Read more: www.neurologylive.com/view/insight...
#WomensNeurology #MedicalEducation

Episode 161: Clinical Takeaways From 2026 International Stroke Conference | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lauren Sansing, MD, MS, FAHA, FANA. [LISTEN TIME: 27 minutes]

🧠🎙️Now live on NeurologyLive: Episode 161 of Mind Moments® features Lauren Sansing, MD, breaking down key clinical takeaways from the 2026 International Stroke Conference

Listen here 👉 www.neurologylive.com/view/episode...
#ISC2026 #Stroke #Neurology

Phase 3️⃣ NEAT: EryDex missed its primary endpoint in ataxia-telangiectasia.

🧠 RmICARS change did not reach significance (P=.0851), and no CGI-S benefit was seen—though tolerability appeared favorable. Visit our website for more!

#ClinicalTrials #RareDisease #Neurology #Phase3

🧠 ⚠️ Paraneoplastic neurologic syndromes can precede cancer diagnosis & mimic chemo toxicity

📣 In NeuroVoices, Drs. Shailee Samir Shah & Ditte Primdahl of Northwestern Medicine break down key diagnostic pitfalls & why neurologist involvement matters

Check out the full episode on our website!
#Neuro

An analysis of the phase 4 COMPEL trial found broadly comparable long-term benefits of onabotulinumtoxinA across White, Asian, and Black/African American patients with chronic migraine.

🔹 ~10–12 fewer monthly headache days
🔹 Similar ≥50% responder rates
🔹 No new safety signals

What do you think? 🤔

🧠 Stem cells in #ParkinsonsDisease?

At Keck Medicine of USC, Xenos Mason discussed the Phase 1 REPLACE™ trial of iPSC-derived dopaminergic grafts with a focus on safety, graft survival, & dyskinesia monitoring.

Is PD cell replacement nearing proof of concept?
#MovementDisorders #Neurology

From Black History Month to Policy Reform: Reimagining Equity in Neuroscience | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms neede...

In recognition of #BlackHistoryMonth ✊🏾🖤📚, Bruce Ovbiagele, MD (Founding President, SEQUINS 🧠) discusses advancing brain health equity — from guideline reform to workforce diversity and fairer quality measures.

Now live on NeurologyLive: www.neurologylive.com/view/from-bl...

Episode 160: Early Pathology, Biomarkers, and the Next Phase of DMD Care | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jeff Chamberlain, PhD. [LISTEN TIME: 23 minutes]

🎙️ New Mind Moments Ep.

During #DMD Awareness Week, Jeff Chamberlain (U. of Washington School of Medicine) discusses early DMD pathology, biomarkers, immunologic drivers, & what gene therapy may mean for 2026+.

🎧 Listen: www.neurologylive.com/view/episode...
#Duchenne #GeneTherapy #Neurology #Neuro

Timing of Second Stroke Occurrence and Personalization of Care | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Experts unpack stroke recurrence disparities, AHA prevention tactics, lifestyle essentials, and emerging factor XIa inhibitors shaping future care.

🧠 When is second #stroke risk highest?

In EP. 2 of our series, Ashkan Shoamanesh, Gregory W. Albers, and James Siegler discuss the “front-loaded” risk of recurrence after TIA/minor stroke, personalization by subtype, and gaps in #prevention.

Watch here 👉 www.neurologylive.com/view/timing-...

NIH Halts Low-Dose Rivaroxaban Arm in CAPTIVA Trial for Intracranial Atherosclerotic Stroke | NeurologyLive - Clinical Neurology News and Neurology Expert Insights An interim DSMB review halted the rivaroxaban arm of the NIH-funded CAPTIVA trial in symptomatic intracranial atherosclerotic stroke due to increased safety events and futility compared with standard ...

🚨 Trial Update in #Stroke

The NIH has halted the low-dose rivaroxaban arm of the CAPTIVA trial after an interim DSMB review found increased safety events and futility compared with standard dual antiplatelet therapy in ICAS.

Read more: www.neurologylive.com/view/nih-hal...
#StrokeResearch

Obexelimab Reduces Number of New GdE T1 Lesions in Relapsing MS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Phase 2 MoonStone shows obexelimab sharply cuts new MRI lesions in relapsing MS by week 12, with convenient weekly self-injection.

New data in #MultipleSclerosis 👇

Obexelimab reduced the number of new gadolinium-enhancing T1 lesions in patients with relapsing #MS, highlighting its potential impact on inflammatory disease activity

Read more:
www.neurologylive.com/view/obexeli...

#MSResearch #ClinicalTrials #Neurology

NeurologyLive - Clinical Neurology News and Neurology Expert Insights NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

🚨 FDA Update in #Narcolepsy

The #FDA has accepted Takeda’s NDA for oveporexton (TAK-861), an oral orexin receptor 2 agonist for narcolepsy type 1 — and granted Priority Review.

🗓️ PDUFA date: Q3 2026

Read more: www.neurologylive.com/view/fda-acc...
#PriorityReview #SleepMedicine #Neurology #NT1

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians | NeurologyLive - Clinical Neurology News and Neurology Expert Insights ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Language matters in medicine 💊

The #ACP is urging the retirement of the term “provider” when referring to #physicians, arguing it blurs expertise, commodifies care, and may erode professional identity and trust

Read more 👉 www.neurologylive.com/view/acp-pol...
#Neuro #MedicalEthics #HealthPolicy

International Epilepsy Day 2026: Highlighting Gaps in Pediatric Care, Stigma, and Education | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents amid International Epilepsy Day, highlighting opportunities for education, stigma reducti...

🌍 International #Epilepsy Day 2026:

Pediatric neurologist Charuta Joshi, MD, breaks down the biggest global gaps and explains why education and advocacy can change outcomes for millions of kids worldwide.

Read the full interview 👉 www.neurologylive.com/view/interna...
#PediatricEpilepsy #Neurology

REGENXBIO's MPS II Gene Therapy RGX-121 Hit With CRL | NeurologyLive - Clinical Neurology News and Neurology Expert Insights NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

#BREAKING: The FDA has handed REGENXBIO a complete response letter (CRL) for its investigational gene therapy RGX-121 as a treatment for mucopolysaccharidosis type 2 (MPS II), also known as Hunter syndrome.

Our coverage: www.neurologylive.com/view/regenxb...

Rethinking Multiple Sclerosis Clinical Course Classifications in the Modern Era: Daniel Ontaneda, MD, PhD | NeurologyLive - Clinical Neurology News and Neurology Expert Insights The staff neurologist at Cleveland Clinic discussed how evolving imaging and biological insights have reshaped the way clinicians define and talk about multiple sclerosis. [WATCH TIME: 3 minutes]

🧠 Rethinking the definition of #MS

At the 2026 #ACTRIMSForum, Daniel Ontaneda, MD, PhD, explains how advances in imaging, biomarkers, and patient-reported outcomes are reshaping how clinicians classify multiple sclerosis.

🎥 Watch now: www.neurologylive.com/view/rethink...
#MSResearch #Neurology

Day 2 coverage at the 2026 #ACTRIMSForum ‼️

Ahead of her #LateBreaking presentation on Saturday, Riley Bove, MD, stopped by to explain the background and mechanisms of Bazedoxifene Acetate (BZA), the drug studied in the Phase II delayed-start myelin repair RCT.
#Neurology #MS #BZA #ClinicalTrials

🎤 We are offically on the ground at #ACTRIMSForum

Stay tunes for real-time insights, expert perspectives, and key takeaways from the MS community—straight from the conference floor 👨‍⚕️

Follow all of NeurologyLive's social media platforms for updates❗
#ACTRIMS2026 #ACTRIMS #Neurology #MS

National Women Physicians Day: Insights From Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO, director of the JS Sonshine Center, shares her personal view on National Women Physician’s and why it’s important for clinicians and patients in the fie...

👩‍⚕️🧠 As we reflect on #NationalWomenPhysiciansDay, Aleksandra Pikula, MD, shares insights on women’s brain health, stroke prevention, and why sex-specific care, trial inclusion, and leadership equity matter.

Read more www.neurologylive.com/view/nationa...
#WomenInNeurology #WomensHealth #Neurology

National Women Physicians Day: Janis Miyasaki, Neuropalliative Care, and Advancing Women Leadersip | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Janis Miyasaki, MD, MEd, FRCPC, FAAN, a pioneer in neuropalliative care, provided clinical thoughts and perspectives on National Women Physicians Day and the ways to promote women leadership within th...

👩‍⚕️ National Women Physician's Day spotlight ✨
Janis Miyasaki, MD—neuropalliative care pioneer & #neurology leader

She reflects on advancing women’s leadership, redefining care for progressive neurologic disease, and mentorship that matters

Read 👉 www.neurologylive.com/view/nationa...
#WomenLeaders

Anti-IL6R Therapy Effective in Reducing NMOSD and MOGAD Disease Activity | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Anti–interleukin-6 receptor therapy may offer a new treatment option for patients with NMOSD and MOGAD who do not respond to rituximab, according to new findings.

🧠 Anti-IL6R therapy significantly reduced relapse rates in #NMOSD & #MOGAD—especially in rituximab-unresponsive patients—without worsening EDSS.

CSF IL-6 levels didn’t predict relapses, highlighting the need for better biomarkers.
Read 👇
www.neurologylive.com/view/anti-il...
#Neurology #NeuroNews

Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial | NeurologyLive - Clinical Neurology News and Neurology Expert Insights With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.

👁️ OCU410ST, a modifier gene therapy for Stargardt disease, showed a +6-letter gain in BCVA at 12 mo and significantly slowed atrophic lesion growth vs untreated eyes — with no serious therapy-related AEs 🚫

Read more 👉 www.neurologylive.com/view/ocugen-...
#GeneTherapy #Neurology #ClinicalTrials

Higher CTE Stages Linked to Increased Dementia Risk, Postmortem Analysis Shows | NeurologyLive - Clinical Neurology News and Neurology Expert Insights A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.

Severe #CTE is strongly linked to increased dementia risk 📈

🧠 A postmortem study of 614 brain donors found stage III–IV CTE was heavily associated with #dementia, while mood and behavioral symptoms were not associated with CTE severity

Read more 👇
www.neurologylive.com/view/higher-...
#Neurology

Real-World Study Provides Support for Lamotrigine in Treating Non-Dystrophic Myotonias | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Trial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.

💊 Real-world data backs #lamotrigine for non-dystrophic myotonias

📉 Myotonia Behavior Score dropped from 3.3 → 1.8 over ~26 months
🧬 Benefits seen in CLCN1 & SCN4A variants
✅ No severe or cardiac AEs

Read more: www.neurologylive.com/view/real-wo...
#Neurology #RareDisease #MedTwitter #Myotonia

Managing Postpartum MS: Safety Data, Relapse Risk, and Real-World Practice | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Inside MS: A Clinician's Compass, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Edith Graham, MD. [LISTEN TIME: 40 minutes]

Episode 1 of MS Compass: Guiding Clinical Care takes a practical look at MS management during breastfeeding, including postpartum relapse risk, treatment timing, and evolving perspectives on DMT use during lactation.

🎧 Now available:
www.neurologylive.com/view/managin...

Higher VMAT2 Target Occupancy Observed in Valbenazine Over Deutetrabenazine Extended-Release Capsules | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Head-to-head PET imaging data indicated that valbenazine achieves significantly higher VMAT2 target occupancy than deutetrabenazine XR at therapeutic doses, with both treatments remaining well tolerat...

🧠 New H2H data on VMAT2 inhibitors:
PET imaging shows valbenazine achieved ~2x higher VMAT2 target occupancy vs deutetrabenazine XR at therapeutic doses—while both remained well tolerated

🔽 Read more below
www.neurologylive.com/view/higher-...
#TD #MD #Neurology #MovementDisorders #ClinicalResearch